| PPAR-alpha Protein | |
|---|---|
| Protein Name | PPAR-alpha Protein |
| Gene Symbol | PPARA |
| UniProt ID | Q07869 |
| PDB Structures | 1K7L, 2NNS, 3G8I |
| Molecular Weight | 52 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | Nuclear Receptor Family |
PPAR-alpha is a protein involved in cellular signaling and transcriptional regulation.[1] This protein plays important roles in regulating gene expression and cellular signaling.[2] In the context of neurodegenerative diseases, PPAR-alpha is implicated in Alzheimer's disease, Parkinson's disease, and other disorders through various mechanisms.[3]
PPARA has a typical nuclear receptor structure with an N-terminal activation function (AF-1) domain, a DNA-binding domain (DBD) with two zinc fingers, a flexible hinge region, and a ligand-binding domain (LBD). The LBD contains a large hydrophobic pocket that binds fatty acids and fibrate drugs. PPARA forms heterodimers with RXRA and binds to DR-1 response elements. The protein has ligand-dependent transcriptional activation function (AF-2) in the LBD.
PPARA is a ligand-activated transcription factor that regulates genes involved in lipid metabolism. It binds fatty acids, eicosanoids, and fibrate drugs as ligands. PPARA activates genes involved in peroxisomal and mitochondrial fatty acid oxidation, lipid transport, and inflammation. In the liver, it activates genes for fatty acid uptake, beta-oxidation, and ketogenesis. PPARA also has anti-inflammatory effects through transrepression of NF-kB and other inflammatory pathways.
PPARA is implicated in neurodegenerative diseases through lipid metabolism and inflammation. In Alzheimer's disease, PPARA activation may reduce brain inflammation and enhance amyloid-beta clearance. Fibrates (PPARA agonists) show protective effects in AD models. In Parkinson's disease, PPARA activation protects dopaminergic neurons from oxidative stress. In ALS, PPARA agonists have shown neuroprotective effects. Clinical trials have had mixed results, suggesting the need for brain-penetrant selective agonists.
PPARA agonists (fibrates: fenofibrate, gemfibrozil) are used to treat dyslipidemia. For neurodegeneration, brain-penetrant PPARA agonists are being developed. Combination therapies targeting PPARA and other nuclear receptors may be beneficial. Selective PPARA modulators with better brain penetration are under development. Gene therapy approaches to increase PPARA expression are also being explored.